Recently, Xuanzhu Biopharma (Stock Code: 02575.HK) and Haoyuan Pharma (Stock Code: 688131) signed a comprehensive strategic cooperation agreement. The two parties will engage in deep collaboration around key links such as early-stage innovative drug R&D, process development, and commercial production of active pharmaceutical ingredients (APIs), empowering innovative R&D with industrialization capabilities and jointly accelerating the commercialization of innovative drugs.

Ms. Xu Yanjun, Chairman of Xuanzhu Biopharma (right), and Dr. Zheng Baofu, Chairman and General Manager of Haoyuan Pharma (left), signing the strategic cooperation agreement

Xuanzhu Biopharma focuses on major disease areas such as oncology, digestion, and metabolism. It currently has more than ten drugs in active R&D and commercialization stages, and has established small-molecule, large-molecule, small nucleic acid, and AI drug R&D platforms, forming an efficiently synergistic R&D system. Adhering to the development philosophy of "focusing on the core and opening up for collaboration," the company concentrates resources on high-value links such as drug discovery, clinical development, and commercialization. This cooperation with Haoyuan Pharma is one of Xuanzhu Biopharma's important arrangements for building a robust innovative drug development ecosystem, synergistically ensuring the high-quality advancement of the pipeline and accelerating the landing of innovative achievements.

Xuanzhu Biopharma focuses on core value links such as drug discovery, clinical development, and commercialization. The efficient and high-quality advancement of its pipeline is inseparable from stable and reliable industrialization support. We look forward to working hand in hand with Haoyuan Pharma, relying on its integrated full-chain CDMO platform capabilities, to promote the steady development and efficient landing of high-quality pipelines in fields such as oncology, digestion, and metabolism, accelerate the translation of innovative drug achievements, and benefit the vast number of patients as soon as possible.

About Haoyuan Pharma

Shanghai Haoyuan Pharmaceutical Co., Ltd. (Stock Code: 688131) was founded in 2006 and focuses on providing the global pharmaceutical and biopharmaceutical industry with R&D of life science reagents in the fields of small-molecule, large-molecule, and new molecular entity drug discovery, drug R&D of APIs, intermediates, starting materials, and formulations, as well as process optimization and commercial production. The company has always regarded innovation as its core driving force, focusing on differentiated development with a "product + service" model, and has laid out more than 10 R&D and production bases. Relying on ten major core technology platforms, it is committed to building an integrated service platform covering "starting materials–intermediates–APIs–biologics–formulations" across drug R&D and production, accelerating the empowerment of more than 15,000 global partners to realize the entire process from preclinical research to commercial production, making drug R&D more efficient, bringing drugs to market faster, and benefiting human health sooner.

About Xuanzhu Biopharma

Xuanzhu Biopharma (Stock Code: 02575.HK) is an innovative pharmaceutical company rooted in China with a global vision, focusing on major disease areas such as digestion, oncology, and metabolism, and dedicated to the R&D, production, and commercialization of Class 1 new drugs with core independent intellectual property rights. As a research-driven, AI-empowered emerging commercial innovative drug company, the company has built a technology system that synergistically integrates a small-molecule drug R&D platform, a biologics R&D platform, and an AI drug R&D platform, thereby forming a product pipeline that is rare in China in simultaneously covering small-molecule chemical drugs, large-molecule biologics, antibody-drug conjugates, and other types. Guided by unmet clinical needs, the company is committed to becoming a first-class innovative drug enterprise with independent R&D, production, and sales capabilities.